An object of the present invention is to provide a new method for evaluating and/or screening an excellent healthcare material or pharmaceutical product based on a new concept. The present invention to solve the above object is a method for evaluating and/or screening a control agent for tissue morphology and/or tissue function, the method including: applying a test substance to a tissue or cell capable of expressing a mechanical stress signaling molecule; and evaluating expression, activity, or intracellular localization of the mechanical stress signaling molecule in the tissue or cell.

The present disclosure, in some aspects, is directed to methods for screening and identifying compounds that modulate one or more characteristics associated with a condensate comprising a RBM20 polypeptide and/or the RBM20 polypeptide. In other aspects, the disclosure is directed to systems and composition components thereof, such as cellular models useful for the methods described herein.

The present invention is based, in part, on the discovery of anti-LRRC25 compositions (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate inflammatory phenotypes of myeloid cells, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-LRRC25 compositions for therapeutic, diagnostic, prognostic, and screening purposes.

Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided.

The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.

An object of the present invention is to provide a novel method which enables convenient preparation of cells exhibiting functions close to that of intestinal epithelial cells of living bodies, and use of the method. The differentiation of induced pluripotent stem cells into intestinal epithelial cells is induced by step of differentiating induced pluripotent stem cells into endoderm-like cells; step of differentiating the endoderm-like cells obtained in step into intestinal stem cell-like cells; and step of differentiating the intestinal stem cell-like cells obtained in step into intestinal epithelial cell-like cells, wherein step includes culture in the presence of a MEK1 inhibitor, a DNA methyltransferase inhibitor, a TGF-β receptor inhibitor, and EGF and under the condition that cAMP is supplied to the cells.

The present invention provides a method of measuring the quality of therapeutic cells through real-time glutathione monitoring.

The present invention relates to an in vitro method for identifying a skin wound in an individual as being a non-healing skin wound or healing skin wound, in vitro methods for monitoring the healing of a skin wound in an individual, methods for screening for compounds suitable for modulating skin wound healing, as well as kits related thereto.

The present invention relates to an indirect three-dimensional co-culture. The indirect co-culture may comprise bone marrow niche cells, tumor cells and a culture medium. The bone marrow niche cells and the tumor cells may be incubated in the culture medium without direct contact between the bone marrow niche cells and the tumor cells. The tumor cells may be dormant or reactivated. Also provided are a method for preparing the indirect co-culture and a method for screening for an agent capable of inhibiting reactivation of dormant tumor cells or promoting dormancy of proliferating tumor cells.

The invention relates to the technical field of medicine, and provides a method of screening and identifying small molecule with anti-aging properties. The method comprises cellular models, namely premature aging mouse embryonic fibroblasts and human HGPS mesenchymal stem cells and animal models, namely premature aging progeroid mice and Caenorhabditis elegans. The method successfully screened and identified Cannabidiol (CBD), which had senolytic effects. The invention also determined that the optimal concentration of CBD treatment is 10-20 μM.